Sphingolipids and insulin resistance: The five Ws

Current Opinion in Lipidology

Volumn 21, Issue 2, 2010, Pages 128-135

  Summers, Scott A ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adipocyte; Ceramide; Glucosylceramide; Hepatic steatosis; Skeletal muscle

Indexed keywords

CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DIHYDROCERAMIDE DESATURASE; FUMONISIN B1; GANGLIOSIDE GM3 SYNTHASE; GLUCOSYLCERAMIDE; INSULIN RECEPTOR; OXYGENASE; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOSINE; SYNTHETASE; THERMOZYMOCIDIN; UNCLASSIFIED DRUG; INSULIN;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL FUNCTION; CELL STRESS; CELL STRUCTURE; DIABETES MELLITUS; ENZYME INHIBITION; FATTY LIVER; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID STORAGE; LIPOGENESIS; METABOLIC DISORDER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; BIOSYNTHESIS; METABOLISM; PATHOLOGY; REVIEW; TIME;

RODENTIA;

ANIMALS; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; SPHINGOLIPIDS; TIME FACTORS;

EID: 77957348390     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283373b66     Document Type: Article

References (77)

1. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000; 10:73-80. (Pubitemid 30084778)
2. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277: 25847-25850. (Pubitemid 34967060)
3. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29:381-402. (Pubitemid 351831506)
4. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007; 5:167-179.
5. Aerts JM, Ottenhoff R, Powlson AS, et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 2007; 56:1341-1349. (Pubitemid 46715620)
6. Zhao H, Przybylska M, Wu IH, et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007; 56:1210-1218. (Pubitemid 46715599)
7. Samad F, Hester KD, Yang G, et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006; 55:2579-2587. (Pubitemid 44871159)
8. Straczkowski M, Kowalska I. The role of skeletal muscle sphingolipids in the development of insulin resistance. Rev Diabet Stud 2008; 5:13-24.
9. Turinsky J, O'Sullivan DM, Bayly BP. 1, 2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 1990; 265:16880-16885.
10. Yetukuri L, Katajamaa M, Medina-Gomez G, et al. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007; 1:12.
11. Todd MK, Watt MJ, Le J, et al. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting againstfatty acid-induced inflammation and insulin resistance. Am J Physiol Endocrinol Metab 2007; 292:E485-E493. (Pubitemid 46220573)
12. Zendzian-Piotrowska M, Baranowski M, Zabielski P, Gorski J. Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles. J Physiol Pharmacol 2006; 57 (Suppl 10):101-114. (Pubitemid 46548770)
13. Adams JM 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53:25-31. (Pubitemid 38044694)
14. Hojjati M, Li Z, Zhou H, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280:10284-10289. (Pubitemid 40395884)
15. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49:2101-2112.
16. Yang G, Badeanlou L, Bielawski J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009; 297:E211-E224.
17. Shimabukuro M, Higa M, Zhou YT, et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273:32487-32490. (Pubitemid 28557623)
18. Park TS, Panek RL, Mueller SB, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110:3465-3471. (Pubitemid 39602225)
19. JeBailey L, Wanono O, Niu W, et al. Ceramide- and oxidant-induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling in muscle cells. Diabetes 2007; 56:394-403.
20. Long SD, Pekala PH. Lipid mediators of insulin resistance: ceramide signalling down regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 1996; 319:179-184. (Pubitemid 26394756)
21. Pickersgill L, Litherland GJ, Greenberg AS, et al. Key role for ceramides in mediating insulin resistance in human muscle cells. J Biol Chem 2007; 282:12583-12589. (Pubitemid 47100630)
22. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylgly-cerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 13:10297-10303. (Pubitemid 36800291)
23. Langeveld M, Ghauharali KJ, Sauerwein HP, et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 2008; 93:845-851. (Pubitemid 351398562)
24. Bijl N, Sokolovic M, Vrins C, et al. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 2009; 50:1431-1441.
25. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009; 58:203-208.
26. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) 2009 [Epub ahead of print].
27. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001; 292:1728-1731. (Pubitemid 32506248)
28. Summers SA, Garza LA, Zhou H, Birnbaum MJ. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998; 18:5457-5464. (Pubitemid 28388128)
29. Stratford S, DeWald DB, Summers SA. Ceramide dissociates 3'-phosphoi-nositide production from pleckstrin homology domain translocation. Biochem J 2001; 354:359-368. (Pubitemid 32209874)
30. Zhou H, Summers SA, Birnbaum MJ, Pittman RN. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem 1998; 273:16568-16575. (Pubitemid 28311444)
31. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide disables 3-phosphoi-nositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23:7794-7808. (Pubitemid 37271476)
32. Salinas M, Lopez-Valdaliso R, Martin D, et al. Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC1 2 cells. Mol Cell Neurosci 2000; 15:156-169. (Pubitemid 30109119)
33. Schubert KM, Scheid MP, Duronio V. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. J Biol Chem 2000; 275: 13330-13335. (Pubitemid 30257390)
34. Chavez JA, Holland WL, Bar J, et al. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 2005; 280:20148-20153. (Pubitemid 41379546)
35. van Eijk M, Aten J, Bijl N, et al. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 2009; 4:e4723.
36. Yamashita T, Hashiramoto A, Haluzik M, et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 2003; 100:3445-3449. (Pubitemid 36356603)
37. Bijl N, Scheij S, Houten S, et al. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. J Pharmacol Exp Ther 2008; 326:849-855.
38. Bijl N, van Roomen CP, Triantis V, et al. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 2009; 49:637-645.
39. Zhao H, Przybylska M, Wu IH, et al. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 2009; 50:85-93.
40. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Archiv Biochem Biophys 2003; 419: 101-109. (Pubitemid 37329976)
41. Liu L, Zhang Y, Chen N, et al. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 2007; 117:1679-1689. (Pubitemid 46871352)
42. Powell DJ, Turban S, Gray A, et al. Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 2004; 382:619-629. (Pubitemid 39243928)
43. Boden G. Ceramide: a contributor to insulin resistance or an innocent bystander? Diabetologia 2008; 51:1095-1096.
44. Coen PM, Dube JJ, Amati F, et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010; 59:80-88.
45. Monetti M, Levin MC, Watt MJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007; 6:69-78. (Pubitemid 46995777)
46. Minehira K, Young SG, Villanueva CJ, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res 2008; 49:2038-2044.
47. Deevska GM, Rozenova KA, Giltiay NV, et al. Acid sphingomyelinase defi-ciency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J Biol Chem 2009; 284:8359-8368.
48. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56:1960-1968. (Pubitemid 47195815)
49. Tagami S, Inokuchi Ji J, Kabayama K, et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 2002; 277: 3085-3092. (Pubitemid 34953168)
50. Kabayama K, Sato T, Saito K, et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci USA 2007; 104:13678-13683. (Pubitemid 350003380)
51. Glaros EN, Kim WS, Rye KA, et al. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res 2008; 49:1677-1681.
52. Fontes G, Semache M, Hagman DK, et al. Involvement of Per-Arnt-Sim kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. Diabetes 2009; 58:2048-2058.
53. Kelpe CL, Moore PC, Parazzoli SD, et al. Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J Biol Chem 2003; 278:30015-30021. (Pubitemid 36962391)
54. Veluthakal R, Palanivel R, Zhao Y, et al. Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta cell. Apoptosis 2005; 10:841-850. (Pubitemid 41187082)
55. Zhang Y, Ranta F, Tang C, et al. Sphingomyelinase dependent apoptosis following treatment of pancreatic beta-cells with amyloid peptides Abeta(1-42) or IAPP. Apoptosis 2009; 14:878-889.
56. Zhu Q, Shan X, Miao H, et al. Acute activation of acid ceramidase affects cytokine-induced cytotoxicity in rat islet beta-cells. FEBS Lett 2009; 583: 2136-2141.
57. Maedler K, Spinas GA, Dyntar D, et al. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 2001; 50:69-76. (Pubitemid 32047983)
58. Xiao-Yun X, Zhuo-Xiong C, Min-Xiang L. Ceramide mediates inhibition of the AKT/eNOS signaling pathway by palmitate in human vascular endothelial cells. Med Sci Monit 2009; 15:BR254-BR261.
59. Wu Y, Song P, Xu J, et al. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007; 282:9777-9788. (Pubitemid 47104626)
60. Mogami K, Kishi H, Kobayashi S. Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation. FEBS Lett 2005; 579:393-397. (Pubitemid 40092417)
61. Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta 2009 [Epub ahead of print].
62. Teruel T, Hernandez R, Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001; 50:2563-2571. (Pubitemid 33642775)
63. Zinda MJ, Vlahos CJ, Lai MT. Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87MG cells. Biochem Biophys Res Commun 2001; 280:1107-1115. (Pubitemid 32924454)
64. Resjo S, Goransson O, Harndahl L, et al. Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal 2002; 14:231-238. (Pubitemid 34102452)
65. Hajduch E, Balendran A, Batty IH, et al. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001; 44:173-183. (Pubitemid 32156201)
66. Blouin CM, Prado C, Takane KK, et al. Plasma membrane subdomain compartmentalization contributes to distinct mechanisms of ceramide action on insulin signalling. Diabetes 2009 [Epub ahead of print].
67. Hoehn KL, Hohnen-Behrens C, Cederberg A, et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab 2008; 7:421-433. (Pubitemid 351598028)
68. Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009; 106:17787-17792.
69. Cohen AW, Razani B, Wang XB, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 2003; 285:C222-C235. (Pubitemid 36736354)
70. Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 2002; 277:25843-25846. (Pubitemid 34967059)
71. de Mello VD, Lankinen M, Schwab U, et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009; 52:2612-2615.
72. Gill JM, Sattar N. Ceramides: a new player in the inflammation-insulin resistance paradigm? Diabetologia 2009 [Epub ahead of print].
73. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158:982-993.
74. Guenther GG, Edinger AL. A new take on ceramide: starving cells by cutting off the nutrient supply. Cell Cycle 2009; 8:1122-1126.
75. Guenther GG, Peralta ER, Rosales KR, et al. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 2008; 105:17402-17407.
76. Skrzypek M, Lester RL, Dickson RC. Suppressor gene analysis reveals an essential role for sphingolipids in transport of glycosylphosphatidylinositol- anchored proteins in Saccharomyces cerevisiae. J Bacteriol 1997; 179: 1513-1520. (Pubitemid 27100436)
77. Chung N, Mao C, Heitman J, et al. Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae. J Biol Chem 2001; 276:35614-35621.